Viokace Approval History 
- FDA approved: Yes (First approved March 1st, 2012)
- Brand name: Viokace
- Generic name: pancrelipase
- Company: Aptalis Pharma U.S. Inc.
- Treatment for: Pancreatic Exocrine Dysfunction
Viokace (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases. Viokace, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.
FDA Approval History for Viokace
| Date | Article |
|---|---|
| Mar 1, 2012 |  Aptalis Pharma Announces FDA Approval of Viokace (Pancrelipase) Tablets |
See also...
Viokace (pancrelipase) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
